Cue Biopharma Stock Today
| CUE Stock | USD 1.63 0.13 8.67% |
Performance0 of 100
| Odds Of DistressOver 81
|
Cue Biopharma is trading at 1.63 as of the 18th of April 2024, a 8.67 percent up since the beginning of the trading day. The stock's lowest day price was 1.5. Cue Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cue Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of January 2018 | Category Healthcare | Classification Health Care |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The company has 48.64 M outstanding shares of which 4.2 M shares are currently shorted by investors with about 17.76 days to cover. More on Cue Biopharma
Moving against Cue Stock
| 0.74 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.72 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.71 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.61 | MRSN | Mersana Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.56 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
| 0.47 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.45 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Cue Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cue Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cue Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Daniel Passeri | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Cue Biopharma report their recommendations after researching Cue Biopharma's financial statements, talking to executives and customers, or listening in on Cue Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cue Biopharma. The Cue consensus assessment is calculated by taking the average forecast from all of the analysts covering Cue Biopharma. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Cue Biopharma's financial statements, Cue Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Cue Biopharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cue Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cue Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cue Biopharma's financial leverage. It provides some insight into what part of Cue Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cue Biopharma (CUE) is traded on NASDAQ Exchange in USA. It is located in 40 Guest Street, Boston, MA, United States, 02135 and employs 53 people. Cue Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 79.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cue Biopharma's market, we take the total number of its shares issued and multiply it by Cue Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cue Biopharma runs under Biotechnology sector within Health Care industry. The entity has 48.64 M outstanding shares of which 4.2 M shares are currently shorted by investors with about 17.76 days to cover.
Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cue Biopharma Probability Of Bankruptcy
Ownership AllocationCue Biopharma retains a total of 48.64 Million outstanding shares. 30% of Cue Biopharma outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Cue Ownership Details
Cue Stock Price Odds Analysis
What are Cue Biopharma's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Cue Biopharma jumping above the current price in 90 days from now is about 92.61%. The Cue Biopharma probability density function shows the probability of Cue Biopharma stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.5241 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cue Biopharma will likely underperform. Additionally, cue Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Cue Biopharma to move above the current price in 90 days from now is about 92.61 (This Cue Biopharma probability density function shows the probability of Cue Stock to fall within a particular range of prices over 90 days) .
Cue Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cue Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cue Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cue Biopharma's value.| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2023-12-31 | 266.2 K | |
| Advisory Research Inc | 2023-12-31 | 257.2 K | |
| Stifel Financial Corp | 2023-12-31 | 194 K | |
| Nuveen Asset Management, Llc | 2023-12-31 | 191.5 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 164.7 K | |
| Carlson Capital Lp | 2023-12-31 | 120 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 116.6 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 109.4 K | |
| Sigma Planning Corp | 2023-12-31 | 108.9 K | |
| Slate Path Capital Lp | 2023-12-31 | 2.4 M | |
| Blackrock Inc | 2023-12-31 | 2.3 M |
Cue Biopharma Historical Income Statement
Cue Biopharma Income Statement is one of the three primary financial statements used for reporting Cue's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cue Biopharma revenue and expense. Cue Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Cue Biopharma's Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 1.3 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M. View More FundamentalsCue Stock Against Markets
Picking the right benchmark for Cue Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cue Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cue Biopharma is critical whether you are bullish or bearish towards Cue Biopharma at a given time. Please also check how Cue Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cue Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Cue Biopharma Corporate Directors
Cue Biopharma corporate directors refer to members of a Cue Biopharma board of directors. The board of directors generally takes responsibility for the Cue Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cue Biopharma's board members must vote for the resolution. The Cue Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Steven McKnight | Director | Profile | |
| Barry Simon | Director | Profile | |
| Peter Kiener | Director | Profile | |
| Frank Morich | Director | Profile |
How to buy Cue Stock?
Before investing in Cue Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cue Biopharma. To buy Cue Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cue Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cue Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cue Biopharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cue Biopharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cue Biopharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cue Stock please use our How to Invest in Cue Biopharma guide.
Already Invested in Cue Biopharma?
The danger of trading Cue Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cue Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cue Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cue Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.11) | Revenue Per Share 0.12 | Quarterly Revenue Growth 11.06 | Return On Assets (0.43) | Return On Equity (0.99) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.